Evidence level: B
一个在 IBS 场景里被反复验证的”应答预测菌”,搬到中医体质分型选菌的随机对照试验里,方向还稳吗?
正文
当我们用”基线菌群指纹”来预测益生菌干预能不能起效时,一个最容易想到的办法就是把别的临床场景里已经验证过的”应答预测菌”原样照搬。在非便秘型 IBS(NC-IBS)场景里,Gargari 等人在 2023 年发表的多中心随机对照试验 post-hoc 分析中明确报告了一个事实——接受 Lacticaseibacillus paracasei DG(LDG)治疗 12 周后能成为应答者的患者,基线粪便里 Collinsella aerofaciens 及其所在的 Coriobacteriaceae 科显著富集;进一步在另一项 LDG-IBS 试验中复用,结果方向一致:基线 C. aerofaciens 高者更可能成为应答者,干预后这一菌被显著压低(PMID 38178601)。换言之,C. aerofaciens 在 NC-IBS 里是一个已被验证的应答预测菌+应答可降靶。问题在于:把 LDG 选菌策略搬到中医体质分型(痰湿 / 阳虚 / 湿热)的随机分组里,这同一个标志物还指向同一方向吗?
要让这个问题可裁决,必须先把”应答”和”方向”两端都钉死。所谓应答,在 IBS 里是用腹痛+粪便性状复合终点定义的;在中医体质场景里,更可能是用 CCMQ(中医体质量表)转化分的变化来定义——通常是 MCID(最小临床重要差异)阈值。方向则有两层:(a)基线菌丰度与”是否应答”的相关性方向(同向为正向标志,反向为负向标志);(b)干预后菌丰度变化与”应答幅度”的方向(同向代表”该菌越多越好打”,反向代表”打一打这菌就下来”)。PMID 38178601 在 NC-IBS 里报告的是双正向——基线富集预测应答、干预后被压低伴随症状改善——也就是说,在 IBS 这个体系里,”C. aerofaciens 多 = 不健康的多”,LDG 的疗效之一就是把这部分”不健康”压下去。
把这个标志物搬到中医体质体系里,必须先回答三个分层问题:
第一层:体质本身就让菌群基础分布不一样。 这一条已经有多项独立证据支持——痰湿质肥胖人群基线 Faecalibacterium 耗竭、Prevotella 富集(PMID 35719350,2022);阳虚质人群 Ruminococcaceae 和 Faecalibacterium 双双升高(PMID 35294128,2022);气阴两虚型代谢综合征人群 Akkermansia 升高、Faecalibacterium 下降(PMID 36440222,2022);湿热质人群 Barnesiella/Coprobacter/Butyricimonas 等产 SCFA 菌下降、花生四烯酸代谢升高(PMID 39957168,2025,多中心 249 例);湿热证慢肝人群 Agathobacter/Dorea/Lachnospiraceae_NC2004_group/Subdoligranulum 等五属同步下降(PMID 36467028,2022,405 例队列)。这五条独立证据指向同一件事——不同体质在属级和科级上的基线菌群分布是显著不同的,换句话说,”高 C. aerofaciens” 在痰湿质、阳虚质、湿热质、平和质里可能根本不是一个含义。
第二层:虚性体质(气虚/阳虚/阴虚)已经有一个自己的 biomarker 框架。 Liang 等人 2024 年在 Front Nutr 报告了一项多组学研究,明确把 Ruminococcus gnavus、Clostridium bolteae、Escherichia coli、Streptococcus parasanguinis、Flavonifractor plautii 列为虚性体质的潜在 biomarker(PMID 39360281,44 作者团队),其中 R. gnavus 被进一步定位为”虚性体质相关贫血倾向”的共享菌基。这条证据和 PMID 38178601 形成一个耐人寻味的对比——IBS 应答标志物 C. aerofaciens 与虚性体质 biomarker R. gnavus 在分类学上完全不同(一个在 Coriobacteriaceae 科,一个在 Lachnospiraceae 科)。如果再看一下更早的 IBS-D 应答研究,Shin 等人 2022 年在韩国队列里发现 Enterococcus faecalis / Lactococcus lactis 是”非应答 biomarker”、Fusicatenibacter saccharivorans 是”应答后丰度上升”的菌(PMID 36250371),而 C. aerofaciens 根本不在这个体系的应答/非应答名单里。这意味着 同一类病(IBS),不同亚型、不同益生菌菌株,应答标志物本身就是异质的。
第三层:应答的方向甚至可能反转。 这是裁决设计里最关键的一环——C. aerofaciens 在 NC-IBS 里是”压低才对”的菌,但它在不同体质里的基线方向并未被报告过。如果某一体质(比如湿热质)本身就富集 C. aerofaciens,那么 LDG 选菌策略”用 C. aerofaciens 高来筛应答者”在这体质里就会失效——因为它本来就高;如果反过来,平和质和虚性体质里 C. aerofaciens 的基线普遍较低,那么”用 C. aerofaciens 高来筛应答者”会系统性地把这部分人排除掉。换言之,一个在 IBS 里被验证的应答标志物,搬到另一个体系时如果不重新做基线分布标定,它的”筛选”功能本身就是可疑的。
要让”跨体系迁移是否成立”真正可裁决,必须做三步:
- 基线分布标定:用 16S rRNA 或宏基因组在痰湿 / 阳虚 / 湿热 / 平和四组人群里测 C. aerofaciens 的属水平相对丰度分布,确认它在各体质的基线方向(与平和质对比是富集还是耗竭)。这条必须独立完成,不能照搬 IBS 数据。
- 方向一致性裁决:在四组分层 RCT 里,对接受同一菌株干预的受试者同时记录”基线 C. aerofaciens 丰度”和”MCID 定义下的应答状态”,用 logistic 回归检验 C. aerofaciens 与应答的 OR(95% CI)、跨体质亚组的交互项 P 值,以及”方向翻转率”——即在哪个体质里方向反转。
- 与 IBS 数据方向对比:把同方向(同向增强或同向减弱)的体质用 NCBI 文献里的 IBS 标志物数据做头对头对照,决定该体质是不是可以套用 IBS 标志物;如果方向翻转或交互显著,则需要按体质各自独立建模。
这条裁决链的关键意义在于:它把”标志物跨体系可用性”从一个事后经验命题,推到了事前可测命题。PMID 38178601 等已经给出的方向图谱,让我们不必再为”菌-应答”的因果链条反复证明——直接锚定方向、一致还是翻转、做不做交互项即可。这是从”微生物组应答研究”过渡到”个体化精准菌群干预”的必由一步,对中医体质分型选菌的工程化尤其重要——只有当一个标志物在不同体质间方向稳定、量级可比时,”辨体选菌 + 标志物筛应答者”才能真正落成一个临床可用的入排标准,而不是只在某一个单一体质里跑得通的小样本探索。
证据与局限
已验证:
– NC-IBS 场景下 L. paracasei DG 应答者基线富集 C. aerofaciens / Coriobacteriaceae,干预后该菌被显著压低,方向在两项独立 RCT 中一致(PMID 38178601);
– 中医体质在属级和科级上的基线菌群差异已被多项独立 16S 研究一致支持(PMID 35719350 痰湿、PMID 35294128 阳虚、PMID 36440222 气阴两虚、PMID 39957168 湿热多中心、PMID 36467028 湿热证慢肝);
– 虚性体质(气虚/阳虚/阴虚)已有独立的 biomarker 框架,R. gnavus 是核心成员(PMID 39360281);
– 同类病(IBS)不同亚型、不同菌株的应答标志物本身就是异质的(PMID 36250371)。
部分验证:
– “基线富集 = 应答预测”在 NC-IBS 中方向稳定,但跨体系的方向稳定性尚未在中医体质 RCT 中直接验证;
– 湿热质与平和质之间的菌群差异在分类学层面已经清晰(C. aerofaciens 是否参与尚无专门报告)。
待验证:
– 痰湿/阳虚/湿热三体质中 C. aerofaciens 的基线相对丰度方向(vs 平和质)尚未见专门报告,需要独立 16S/宏基因组标定;
– “基线 C. aerofaciens 高 = 应答”的预测关系是否在不同体质亚组中保持方向一致、量级可比、交互项是否显著,需要多中心分层 RCT 裁决;
– 应答菌(如 F. saccharivorans)与非应答菌(如 E. faecalis)跨体系迁移的稳定性同样未验证,可作同体系扩展测试。
相关阅读
证据等级: B
参考文献: PMID 38178601, PMID 39360281, PMID 36440222, PMID 35719350, PMID 35294128, PMID 39957168, PMID 36467028, PMID 36250371
证据等级:B=科学类比/间接证据(基于已发表的多项独立 RCT 和横断面研究做跨体系方向裁决,跨体系方向一致性本身仍待直接验证)
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Cross-system perspective on TCM constitution-based probiotic selection: adjudication of C. aerofaciens response biomarkers
Evidence level: B
When a “response-predicting probiotic” validated repeatedly in an IBS context is transplanted into a randomized controlled trial (RCT) for TCM constitution-based probiotic selection, does the direction of efficacy remain stable?
Main Text
When using “baseline community fingerprinting” to predict the efficacy of probiotic interventions, the most intuitive approach is to directly transplant validated “response-predicting bacteria” from other clinical contexts. In the non-constipated IBS (NC-IBS) context, a post-hoc analysis of a multi-center RCT by Gargari et al. (2023) explicitly reported a fact: patients who became responders after 12 weeks of Lacticaseibacillus paracasei DG (LDG) treatment showed significant enrichment of Collinsella aerofaciens and its family, Coriobacteriaceae, in baseline feces. Further replication in another LDG-IBS trial yielded consistent results: higher baseline abundance of C. aerofaciens correlated with a higher likelihood of becoming a responder, followed by significant suppression of this bacterium post-intervention (PMID 38178601). In essence, C. aerofaciens serves as a validated response predictor and a target for reduction in NC-IBS. The critical question arises when transplanting the LDG probiotic selection strategy into a TCM constitution-based randomization framework (Phlegm-Dampness, Yang Deficiency, Damp-Heat): does this same marker still point in the same direction?
To make this question adjudicable, both ends of “response” and “direction” must be firmly defined. In IBS, response is defined by a composite endpoint of abdominal pain and stool characteristics. In the TCM constitution context, response is more likely defined by changes in CCMQ (TCM Constitution Questionnaire) transformed scores—typically using the MCID (Minimum Clinically Important Difference) threshold. Direction involves two layers: (a) the correlation direction between baseline bacterial abundance and “response status” (positive if aligned, negative if reversed); and (b) the direction between post-intervention bacterial abundance changes and “response magnitude” (aligned implies “more of this bacterium is better,” reversed implies “suppression of this bacterium yields improvement”). PMID 38178601 reports a double positive in NC-IBS—baseline enrichment predicts response, and post-intervention suppression accompanies symptom improvement. Thus, within the IBS framework, “high C. aerofaciens = unhealthy abundance,” and one efficacy mechanism of LDG is to suppress this “unhealthy” component.
Transplanting this marker into the TCM constitution framework requires addressing three stratified questions first:
First Layer: Constitutions inherently alter baseline community distributions. This is supported by multiple independent lines of evidence—phlegm-dampness constitution obesity groups show baseline depletion of Faecalibacterium and enrichment of Prevotella (PMID 35719350, 2022); yang-deficiency constitution groups show simultaneous increases in Ruminococcaceae and Faecalibacterium (PMID 35294128, 2022); qi-yin deficiency syndrome groups show increased Akkermansia and decreased Faecalibacterium (PMID 36440222, 2022); damp-heat constitution groups show decreased SCFA-producing bacteria (Barnesiella/Coprobacter/Butyricimonas) and increased arachidonic acid metabolism (PMID 39957168, 2025, multi-center 249 cases); and damp-heat syndrome chronic liver disease groups show synchronous decreases in five genera including Agathobacter/Dorea/Lachnospiraceae_NC2004_group/Subdoligranulum (PMID 36467028, 2022, 405-case cohort). These five independent evidences point to one conclusion: baseline community distributions at the genus and family levels differ significantly across constitutions. In other words, “high C. aerofaciens” may carry fundamentally different meanings in phlegm-dampness, yang-deficiency, damp-heat, and balanced constitutions.
Second Layer: Deficient constitutions (Qi/Yang deficiency) already possess their own biomarker framework. Liang et al. (2024) reported a multi-omics study in Front Nutr, explicitly listing Ruminococcus gnavus, Clostridium bolteae, Escherichia coli, Streptococcus parasanguinis, and Flavonifractor plautii as potential biomarkers for deficient constitutions (PMID 39360281, 44-author team), with R. gnavus further positioned as a shared bacterium base for “deficient constitution-associated anemia tendency.” This evidence forms an intriguing contrast with PMID 38178601: the IBS response marker C. aerofaciens and the deficient constitution biomarker R. gnavus belong to completely different taxonomic classifications (one in Coriobacteriaceae family, the other in Lachnospiraceae family). Furthermore, reviewing earlier IBS-D response studies, Shin et al. (2022) found in a Korean cohort that Enterococcus faecalis / Lactococcus lactis served as “non-response biomarkers,” while Fusicatenibacter saccharivorans showed increased abundance post-response (PMID 36250371), with C. aerofaciens absent from this system’s response/non-response lists. This implies that response markers for the same disease category (IBS) are inherently heterogeneous across different subtypes and probiotic strains.
Third Layer: The direction of response may even reverse. This is the most critical link in the adjudication design—C. aerofaciens should be suppressed in NC-IBS, yet its baseline direction across different constitutions has not been reported. If a specific constitution (e.g., damp-heat) inherently enriches C. aerofaciens, then the LDG selection strategy of “screening responders via high C. aerofaciens” would fail in that constitution because the baseline is already high; conversely, if baseline levels of C. aerofaciens are generally low in balanced and deficient constitutions, “screening via high abundance” would systematically exclude these groups. In essence, a validated response marker in one system becomes suspect for its “screening” function if not re-calibrated against baseline distributions when transplanted to another system.
To truly adjudicate “whether cross-system transfer holds,” three steps must be taken:
- Baseline Distribution Calibration: Measure genus-level relative abundance distributions of C. aerofaciens in phlegm-dampness, yang-deficiency, damp-heat, and balanced groups using 16S rRNA or metagenomics to confirm its baseline direction (enrichment vs. depletion relative to balanced constitution). This must be conducted independently without borrowing IBS data.
- Direction Consistency Adjudication: In four-stratified RCTs, record both “baseline C. aerofaciens abundance” and “response status under MCID definition” for subjects receiving the same strain intervention. Use logistic regression to test the OR (95% CI) of C. aerofaciens with response, P-values for cross-constitution interaction terms, and the “direction reversal rate”—identifying which constitution exhibits a reversal.
- Direction Comparison with IBS Data: Perform head-to-head comparisons using NCBI literature data on IBS markers for constitutions sharing the same direction (reinforcement or weakening). Determine if a constitution can adopt IBS markers; if direction reverses or interactions are significant, independent modeling per constitution is required.
The critical significance of this adjudication chain lies in elevating “cross-system marker availability” from a post-hoc empirical proposition to a pre-test measurable proposition. The direction maps provided by PMID 38178601 and similar studies allow us to avoid repeatedly proving the causal chain of “bacteria-response.” Instead, we can directly anchor on direction consistency or reversal and whether interaction terms are significant. This represents a necessary step transitioning from “microbiome response research” to “individualized precision microbiome intervention,” particularly important for the engineering of TCM constitution-based probiotic selection. Only when a marker maintains stable direction and comparable magnitude across constitutions can “constitution-based probiotic selection + marker-based responder screening” truly become a clinically usable inclusion/exclusion standard, rather than remaining a small-sample exploration valid only within a single constitution.
Evidence and Limitations
Verified:
– In the NC-IBS context, baseline enrichment of C. aerofaciens/Coriobacteriaceae in responders to L. paracasei DG was followed by significant post-intervention suppression, with consistent direction across two independent RCTs (PMID 38178601);
– Baseline community differences at genus and family levels across TCM constitutions are consistently supported by multiple independent 16S studies (PMID 35719350 Phlegm-Dampness, PMID 35294128 Yang-Deficiency, PMID 36440222 Qi-Yin Deficiency, PMID 39957168 Damp-Heat Multi-center, PMID 36467028 Damp-Heat Chronic Liver);
– A distinct biomarker framework for deficient constitutions (Qi/Yang/Yin deficiency) exists, with R. gnavus as a core member (PMID 39360281);
– Response markers for the same disease category (IBS) are inherently heterogeneous across different subtypes and strains (PMID 36250371).
Partially Verified:
– The “baseline enrichment = response prediction” direction is stable in NC-IBS, but cross-system directional stability has not been directly verified in TCM constitution RCTs;
– Community differences between damp-heat and balanced constitutions are clear at the taxonomic level, though specific involvement of C. aerofaciens lacks dedicated reporting.
To Be Verified:
– The baseline relative abundance direction of C. aerofaciens in phlegm-dampness, yang-deficiency, and damp-heat constitutions (vs. balanced) lacks dedicated reporting and requires independent 16S/metagenomic calibration;
– Whether the predictive relationship “high baseline C. aerofaciens = response” maintains consistent direction, comparable magnitude, and significant interaction terms across constitution subgroups requires adjudication via multi-center stratified RCTs;
– The stability of cross-system transfer for response bacteria (e.g., F. saccharivorans) versus non-response bacteria (e.g., E. faecalis) remains unverified and can serve as an extension test within the same system.
Related Reading
- TCM Constitution Personalized Probiotic Selection and Responder Stratification
- Verdict on “Cross-Constitution Directional Consistency” of Response Markers
- Responder Stratification and Microbiome Intervention RCTs
- Verdict on Microbiome Causal Direction by Constitution (Mendelian Randomization)
- Research Pool P3: Biofrequency Codes and Constitution Microbiomes
Evidence Level: B
References: PMID 38178601, PMID 39360281, PMID 36440222, PMID 35719350, PMID 35294128, PMID 39957168, PMID 36467028, PMID 36250371
Evidence Level: B = Scientific Analogy/Indirect Evidence (based on cross-system direction adjudication derived from multiple independent published RCTs and cross-sectional studies; cross-system directional consistency itself remains pending direct verification).
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply